In this podcast, Sue Nemetz, CEO and founder of Corval and The NemetzGroup, and Kerrie Brady, Serial Biotech Entrepreneur and CEO Stealth Newco, discuss key topics related to commercialization strategies for biotech CEOs.
Key highlights include:
CLICK BELOW TO PLAY
Commercialization and Launch—What Keeps a Biotech CEO Up at Night?
The episode provides a practical guide for biotech CEOs on when and how to approach commercialization to avoid pitfalls and maximize value for both investors and patients.
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
Susan Nemetz is CEO and founder of The NemetzGroup and Corval. A proven leader in the life science industry, Nemetz helps transform biopharma companies from early-stage to publicly traded with her ability to see strategic opportunities and cultivate talent and empower the team to achieve them. In 2003, Susan created The NemetzGroup, which helps companies successfully navigate the commercialization spectrum through a unique and flexible consulting model. Over the past 20 years, the company has been instrumental in guiding the evolution of hundreds of biopharma companies and the development of numerous assets, from targets to lifesaving approved medicines. Susan founded her second company, Corval, in 2018, which is built on her deep biopharma commercialization knowledge and vision to vastly improve how emerging companies define their path to market. The company’s disruptive technology platform enables early- mid-stage biopharma companies to self-navigate the complex commercialization planning process by building a validated map, headcount, and budget plan.
Kerrie Brady is a successful serial biotechnology entrepreneur and strategic business leader with over 30 years of international experience across a variety of therapeutic areas. Before her position as CEO and President of OcuTerra Therapeutics, Kerrie co-founded Centrexion Therapeutics in 2013 and served as its Chief Business Officer and Executive VP of Strategy. As co-founder, she played a key role in growing the initial team from two people to a high-performing 25-person team with five clinical programs. She was instrumental in raising over $150 million in investments, led the $998 million out-licensing deal to Lilly, with over $48 million up front.
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
The Corval® Platform is a cloud-based strategic planning platform that enables teams to quickly build and manage tailored multi-year commercialization roadmaps, detailed budgets, and full hiring plans.
To see how Corval can transform your launch planning strategy, request a demo with our commercialization experts today.